Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →The Adaptive-Genentech collaboration secured its first IND clearance for a neoantigen-directed TCR therapy — a milestone, but slow progress for a 2019 deal…
Genentech walks away from the $2B+ Adaptive cell therapy pact after six years and only one IND, mirroring its April 2024 exit from a similar Adaptimmune deal —…
BTIG reiterates Buy on Adaptive following the Genentech termination, arguing the diagnostics-focused core business is undervalued and the cell therapy…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Genentech (Roche Group) entered a worldwide collaboration and license agreement with Adaptive Biotechnologies to develop, manufacture and commercialize novel neoantigen-directed T-cell therapies. Adaptive received $300M upfront and is eligible for more than $2B in development, regulatory and commercial milestones plus royalties. Agreement was later terminated in February 2026.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Adaptive Biotechnologies Corp. (this deal) | 2019 | $2.3B | — |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2019 deals · Roche Holding AG deals · Oncology deals